Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
about
Genomic and transcriptomic characterization of skull base chordoma.MethylSig: a whole genome DNA methylation analysis pipeline.Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicThe Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patientsMolecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patientsMutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemiaCharacteristics, clinical outcome, and prognostic significance of IDH mutations in AMLIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionMetabolism pathways in chronic lymphocytic leukemia.Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesEvaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotypeIDH1 and IDH2 mutations in pediatric acute leukemiaIsocitrate dehydrogenase mutations in myeloid malignancies.IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigeneticsThe emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.Isocitrate dehydrogenase mutations in leukemia.Epigenetic alterations in acute myeloid leukemias.A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.Epigenetics: A primer for clinicians.Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia.Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.pSDTV vector: a modification of the pBluescript SK+ plasmid in order to perform PCR-fragments TA-cloning using Eam1105I restriction endonuclease.Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues.Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia.IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.Influence of IDH on FLT3-ITD status in newly diagnosed AML.
P2860
Q33276293-99B9174A-64D5-4FFF-99C6-92564C8A9250Q34103126-0F9831AF-D17E-4944-B7FF-EA4A6016E4ACQ34347935-2B8D6B72-A01D-4F4D-9BDF-6DA5C7E5A6F9Q34661033-7C511251-49D7-4B45-A0FB-238A53C1DDFCQ34817365-B65E6925-981E-430F-99A1-D808CA23109AQ35078037-953A9CC7-5435-4C28-8E2A-6DA112347999Q35873466-C03D1C32-2E74-4630-87A0-A2FAA5E811CDQ36174305-0DAF50AD-8577-4A51-9C32-EF44D1A5A1E1Q36181742-0BDF6FA2-A9E7-48D4-8EE1-FBD473904FB5Q36522731-48F3D94E-B388-4957-BE78-D85FB20BEB40Q36693111-CB5F02AA-F13F-4D1D-8ACA-A9F7CA707EB5Q36770211-97F16B35-5A91-4D61-A43E-596021F19D7AQ37047952-89709F2D-9537-4671-A4F8-4FAE414E6241Q37432049-2CAC989C-95B0-40C8-A342-92CECCF30FA6Q37444122-7C2B4BA9-66AC-4B59-B8E7-DBDED1D77CAAQ37625630-B03843E4-C53B-4967-A6C3-B71B0B36BB23Q37734751-912E3D48-3D9E-4399-9D46-EB720FC88E6AQ38121089-9AD881CD-6316-4F73-B599-5E1225A616A5Q38133721-A5B14AB9-EACE-4307-9D4D-48106F468A24Q38264968-DC2CB65A-D054-411A-AA1F-CA792965A935Q38372745-2A13F46F-6CE2-4F3A-9D4F-9815336854C8Q38509706-DBB401A4-438F-4BF4-844D-5AF27D5BFBDFQ38714577-7FDF892B-0FB2-4314-8A96-6D3E2FE9BA5FQ38770916-F715FCE6-3BBC-491D-9264-91FDAEF727C0Q38963204-BF6183AD-83EA-4875-8C28-BE06D95E0B4BQ39378248-6448E30F-C0E1-4B7A-8396-0E83B3714621Q39443070-591BAFA3-9428-4534-A6EE-182BD3CAE057Q40085109-FA171F9E-ADAF-497D-AEDC-855A8A6A9E9CQ40261354-347227E2-39D5-48DB-941F-B2A6549F0317Q41114465-706E4CCA-5B90-44F2-AFF5-B7E2440D3FCBQ41870967-92DEABBB-7E4E-475F-A6AB-2378DDFC4D22Q44211517-0198341D-FB68-4B76-BB52-2F1746A3E6B8Q46117117-14BED132-DA06-408C-98E4-0C7F4D79A9E6Q46744333-451ACC1E-A39F-440E-BC0B-FB0EAC05AA74Q47754067-C249C930-C675-4186-B2D8-FBC06060862FQ50033966-162D3782-EBA6-4BCF-913D-162E0DBFE8C8Q52715807-DF02204A-937E-4A48-8215-11AA1BE5549BQ53102351-264DC786-3337-44C6-95F2-804C7510273BQ54315146-2F2774F2-FA33-4891-A200-647757F63FF3Q54990383-BBEFF9AF-5656-41CF-9522-6C0E4EA1178A
P2860
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@ast
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@en
type
label
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@ast
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@en
prefLabel
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@ast
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@en
P2093
P2860
P356
P1476
Acute myeloid leukemia with ID ...... nd clinicopathologic features.
@en
P2093
Abhaya Paladugu
Bedia A Barkoh
Keyur P Patel
L Jeffrey Medeiros
Rajyalakshmi Luthra
P2860
P356
10.1309/AJCPD7NR2RMNQDVF
P407
P577
2011-01-01T00:00:00Z